Immunogenicity Assays (ADA / NAb) CROs
29 published
29 published CROs match Immunogenicity Assays (ADA / NAb).
Locations in this set include United States, China, United Kingdom, Netherlands, Australia, and Belgium.
Capabilities that show up most often in this set: Biologics (Other), Biologics (Monoclonal Antibodies), Small Molecule, Cell Therapy, and Gene Therapy.
Matching companies
STEMCELL Technologies Inc.STEMCELL Technologies develops and sells cell culture media, cell separation systems, instruments, and reagents for life sciences research, plus contract research services including biopharmaceutical testing, cell characterization, toxicity testing, and organoid assays.
SannovaSannova provides bioanalytical and analytical CRO services, including immunogenicity and ligand binding assays, PK testing, DMPK services, extractables and leachables, nitrosamine testing, and pharmaceutical stability testing. Its listed work spans small molecules, biologics and biosimilars, and cell and gene therapies.
Simbec-OrionFull-service CRO delivering clinical trial management across early to late phases, with specialist expertise in rare diseases and oncology.
SoCal Biosciences, Inc.San Diego-based bioanalytical CRO specializing in assay development and analysis for mRNA, oligonucleotides, and large molecules across discovery through clinical development phases.
Svar Life Science ABSvar Life Science offers CRO services including bioanalytical testing, biomarker discovery, and GMP QC testing, alongside diagnostic services and cell manufacturing capabilities.- Swiss BioQuant AGBioanalytical CRO offering LC-MS/MS and ligand-binding assay development, validation, and sample analysis for small and large molecules. Work runs in a 21 CFR Part 11 compliant environment, with qPCR support for gene therapy bioanalysis.
Sword BioBioanalytical CRO offering ligand binding assay development, PK, immunogenicity (ADA and NAb), and custom biomarker assays under non-GLP, spirit-of-GLP, and GLP conditions. Supports clients from discovery through clinical Phase IV.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /services/immunogenicity-assays.md